Press release
Gallbladder Cancer Pipeline Insight Report 2023 (Updated) | Companies - Celgene, MedImmune, Ohara Pharmaceuticals, and Others
Gallbladder Cancer Pipeline
The research on the Gallbladder Cancer pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Gallbladder Cancer, any NDA approvals obtained for Gallbladder Cancer, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Gallbladder Cancer Pipeline treatment landscape of the report, click here @ Gallbladder Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Gallbladder Cancer Pipeline Report
• DelveInsight's Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Gallbladder Cancer Companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others.
• Promising Gallbladder Cancer Pipeline Therapies include M7824, Panitumumab, oxaliplatin, exatecan mesylate, ZD6474, Vandetanib, Gemcitabine, Capecitabine, Cisplatin, gemcitabine hydrochloride, and others.
• The Gallbladder Cancer companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The Gallbladder Cancer pipeline therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.
• Celgene' new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.
• Ohara Pharmaceutical's "breakthrough" drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.
Gallbladder Cancer Overview
Gallbladder cancer is a small, pear-shaped organ situated beneath the liver, responsible for storing bile enzymes and aiding in digestion. It is an uncommon form of cancer characterized by the abnormal growth of cells in the area of the gallbladder. The majority of gallbladder cancer cases originate from glandular cells that make up the inner lining of the organ.
For further information, refer to the detailed Gallbladder Cancer Unmet Needs, Gallbladder Cancer Market Drivers, and Gallbladder Cancer Market Barriers, click here for Gallbladder Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gallbladder Cancer Emerging Drugs Profile
• Durvalumab: Celgne
• ONC 201: Ohara Pharmaceuticals
Gallbladder Cancer Pipeline Therapeutics Assessment
There are approx. 10+ Gallbladder Cancer companies are developing Gallbladder Cancer therapies. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.
Request a sample and discover the recent advances in Gallbladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gallbladder Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gallbladder Cancer Pipeline Therapeutics Assessment
• Gallbladder Cancer Assessment by Product Type
• Gallbladder Cancer by Stage and Product Type
• Gallbladder Cancer Assessment by Route of Administration
• Gallbladder Cancer by Stage and Route of Administration
• Gallbladder Cancer Assessment by Molecule Type
• Gallbladder Cancer by Stage and Molecule Type
Some of the Companies in the Gallbladder Cancer Therapeutics Market include-
Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly, and Company, EMD Serono, and Others.
Dive deep into rich insights for drugs for Gallbladder Cancer Pipeline, click here @ Gallbladder Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gallbladder Cancer Pipeline Report
• Coverage- Global
• Gallbladder Cancer Companies- Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly and Company, EMD Serono, and Others
• Gallbladder Cancer Pipeline Therapies- cisplatin, gemcitabine hydrochloride, M7824, Gemcitabine, CTX-009, Paclitaxel, Fentanyl sublingual spray, and others
• Gallbladder Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Gallbladder Cancer Mergers and acquisitions, Gallbladder Cancer Licensing Activities @ Gallbladder Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Gallbladder Cancer Executive Summary
3. Gallbladder cancer: Overview
4. Gallbladder cancer Pipeline Therapeutics
5. Gallbladder cancer Therapeutic Assessment
6. Gallbladder cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Gallbladder cancer Collaboration Deals
9. Mid Stage Products (Phase II)
10. Durvalumab : Celgene
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. ONC 201: Ohara Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Gallbladder cancer Key Companies
17. Gallbladder cancer Key Products
18. Gallbladder cancer- Unmet Needs
19. Gallbladder cancer- Market Drivers and Barriers
20. Gallbladder cancer- Future Perspectives and Conclusion
21. Gallbladder cancer Analyst Views
22. Gallbladder cancer Key Companies
23. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gallbladder Cancer Pipeline Insight Report 2023 (Updated) | Companies - Celgene, MedImmune, Ohara Pharmaceuticals, and Others here
News-ID: 3162919 • Views: …
More Releases from DelveInsight Business Research
Peripheral T-Cell Lymphoma (PTCL) Market Analysis 2034 - Competitive Landscape, …
The Peripheral T-Cell Lymphoma (PTCL) Market across the 7MM was valued at approximately USD 680 million in 2020, and it is projected to experience steady growth by 2034.
Peripheral T-Cell Lymphoma (PTCL) Market Overview
As of 2023, the United States held the largest share of the PTCL therapeutics market within the 7MM, reaching a valuation of around USD 500 million, followed by Japan. Newly diagnosed patients are generally managed with anthracycline-based chemotherapy…
Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landsc …
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.
Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medicatio …
Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.
Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.
Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary…
More Releases for Gallbladder
Gallbladder Surgery Under Dr. Moein in Los Angeles
Gallbladder surgery has become a preferred option for many in Los Angeles seeking relief from painful gallstones and cholecystitis. At Healthy Life Bariatrics, board-certified surgeon Dr. Babak Moein performs minimally invasive laparoscopic gallbladder removal, offering patients faster recovery, smaller incisions, and fewer complications.
More and more patients in Los Angeles are turning to minimally invasive gallbladder surgery to treat painful symptoms of gallstones and cholecystitis. Surgeons in the area, including trusted…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Cancer Treatment Market Expands With Emergence of Novel Chemotherape …
Gallbladder Cancer Treatment Market Overview
The Gallbladder Cancer Treatment Market is projected to grow from USD 720 Million in 2025 to USD 1.4 Billion by 2032, at a CAGR of 10.1% during the forecast period.
Coherent Market Insights is pleased to release its latest Gallbladder Cancer Treatment Market research report, offering an in-depth analysis of the U.S. Gallbladder Cancer Treatment Market Landscape from 2025 to 2032. This report delivers reliable projections across…
Gallbladder Cancer Market to Rise by 2032 | Celgene, MedImmune, Ohara Pharmaceut …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
Gallbladder Cancer Therapeutics Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Gallbladder Cancer Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Gallbladder Cancer Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
